Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background — Chlamydia pneumoniae is associated with coronary artery disease (CAD), although its causal role is uncertain. A small preliminary study reported a >50% reduction in ischemic events by azithromycin, an antibiotic effective against C pneumoniae , in seropositive CAD patients. We tested this prospectively in a larger, randomized, double-blind study. Methods and Results —CAD patients (n=302) seropositive to C pneumoniae (IgG titers ≥1:16) were randomized to placebo or azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months. The primary clinical end point included cardiovascular death, resuscitated cardiac arrest, nonfatal myocardial infarction (MI), stroke, unstable angina, and unplanned coronary revascularization at 2 years. Treatment groups were balanced, and azithromycin was generally well tolerated. During the trial, 47 first primary events occurred (cardiovascular death, 9; resuscitated cardiac arrest, 1; MI, 11; stroke, 3; unstable angina, 4; and unplanned coronary revascularization, 19), with 22 events in the azithromycin group and 25 in the placebo group. There was no significant difference in the 1 primary end point between the 2 groups (hazard ratio for azithromycin, 0.89; 95% CI, 0.51 to 1.61; P =0.74). Events included 9 versus 7 occurring within 6 months and 13 versus 18 between 6 and 24 months in the azithromycin and placebo groups, respectively. Conclusions —This study suggests that antibiotic therapy with azithromycin is not associated with marked early reductions (≥50%) in ischemic events as suggested by an initial published report. However, a clinically worthwhile benefit (ie, 20% to 30%) is still possible, although it may be delayed. Larger (several thousand patient), longer-term (≥3 to 5 years) antibiotic studies are therefore indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Saikku, P., Mattila, K., Nieminen, M. S., Huttunen, J. K., Leinonen, M., Ekman, M.-R., Mäkelä, P. H., & Valtonen, V (1988) · The Lancet · doi:10.1016/s0140-6736(88)90741-6 · Cited by 1,964
van der Wal, A. C., Becker, A. E., van der Loos, C. M., & Das, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.1.36 · Cited by 1,910
Cell Biology of Atherosclerosis
Ross, R. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.004043 · Cited by 1,003 · cited 1×
“Pathophysiological Considerations Our results are consistent with 3 possibilities: (1) a noncausal role of C pneumoniaein CAD pathogenesis, (2) a smaller benefit for antibiotic therapy (eg, 20% to 30% beneficial effect), or (3) a causal role for C pneumoniaewith the present negative results explained by inefficiency o…”
ResultSaikku, P., Leinonen, M., Tenkanen, L., Linnanmäki, E., Ekman, M.-R., Manninen, V., Mänttäri, M., Frick, M. H., & Huttunen, J. K. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-4-273 · Cited by 786
Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary Arteries
Kuo, C.-C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L., & Grayston, J. T. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.4.841 · Cited by 762
A New Chlamydia psittaci Strain, TWAR, Isolated in Acute Respiratory Tract Infections
Grayston, J. T., Kuo, C.-C., Wang, S.-P., & Altman, J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607173150305 · Cited by 718
Gupta, S., Leatham, E. W., Carrington, D., Mendall, M. A., Kaski, J. C., & Camm, A. J. (1997) · Circulation · doi:10.1161/01.cir.96.2.404 · Cited by 706
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
Gurfinkel, E., Bozovich, G., Daroca, A., Beck, E., & Mautner, B. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07201-2 · Cited by 573
Libby, P., Egan, D., & Skarlatos, S. (1997) · Circulation · doi:10.1161/01.cir.96.11.4095 · Cited by 556
Cited by
Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., et al. (2006) · Stroke · doi:10.1161/01.str.0000223048.70103.f1 · Cited by 1,368
Lockhart, P. B., Bolger, A. F., Papapanou, P. N., Osinbowale, O., Trevisan, M., Levison, M. E., Taubert, K. A., Newburger, J. W., Gornik, H. L., Gewitz, M. H., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31825719f3 · Cited by 1,038
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 373
Anti-inflammatory effects of macrolide antibiotics
Čulić, O., Eraković, V., & Parnham, M. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01321-8 · Cited by 334
O'Connor, C. M., Dunne, M. W., Pfeffer, M. A., Muhlestein, J. B., Yao, L., Gupta, S., Benner, R. J., Fisher, M. R., Cook, T. D., & for the Investigators in the WIZARD Study (2003) · JAMA · doi:10.1001/jama.290.11.1459 · Cited by 328
Self-citation<EMPH TYPE="ITAL">Chlamydia pneumoniae</EMPH> as an Emerging Risk Factor in Cardiovascular Disease
Kalayoglu, M. V. (2002) · JAMA · doi:10.1001/jama.288.21.2724 · Cited by 283
The importance of the gastrointestinal system in the pathogenesis of heart failure
Krack, A., Sharma, R., Figulla, H. R., & Anker, S. D. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi389 · Cited by 280
“The results of recent large-scale studies are discouraging.(43) More mechanistic studies have lead to a shift of focus from bacteria to endotoxin as an important factor in the development of arteriosclerosis.”
ResultAndraws, R., Berger, J. S., & Brown, D. L. (2005) · JAMA · doi:10.1001/jama.293.21.2641 · Cited by 235
Association Between Influenza Vaccination and Reduced Risk of Brain Infarction
Lavallée, P., Perchaud, V., Gautier-Bertrand, M., Grabli, D., & Amarenco, P. (2002) · Stroke · doi:10.1161/hs0202.102328 · Cited by 203
Chlamydia pneumoniae and atherosclerosis
Belland, R. J., Ouellette, S. P., Gieffers, J., & Byrne, G. I. (2004) · Cellular Microbiology · doi:10.1046/j.1462-5822.2003.00352.x · Cited by 199
“This pilot trial was expanded in the ACADEMIC study (Muhlestein et al., 2000), which randomized more CVD patients (300 versus 60) into longer (3 months) placebo versus azithromycin treatment groups.”
MethodThe role of heat shock proteins in atherosclerosis
Wick, G., Jakic, B., Buszko, M., Wick, M. C., & Grundtman, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.91 · Cited by 172
Kucers' The Use of Antibiotics
(2017) · CRC Press eBooks · doi:10.1201/9781498747967 · Cited by 169
Periodontal therapy and cardiovascular risk
Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155
Metadata
- Authors
- Muhlestein, J. B., Anderson, J. L., Carlquist, J. F., Salunkhe, K., Horne, B. D., Pearson, R. R., Bunch, T. J., Allen, A., Trehan, S., & Nielson, C.
- Venue
- Circulation
- Published
- 2000-10-10
- Volume
- 102
- Issue
- 15
- Pages
- 1755-1760
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2033866501
- Cited by
- 207
- References
- 32
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.